Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 5 Venous Thrombosis 4 Venous Thromboembolism 1 Thrombosis 1 Thromboembolism 1 Pulmonary Embolism 1 Myeloproliferative Disorders 1 Hemostatic Disorders 1

Interventions

Enoxaparin 3 Tinzaparin 2 Saline Solution 2 Heparin, Low-Molecular-Weight 2 Heparin 2 Gemcitabine 2 Fondaparinux 2 Dalteparin 2 130-nm albumin-bound paclitaxel 2 palbociclib 1 enoxaparin sodium 1 edoxaban 1 apixaban 1 Warfarin 1 Tranexamic Acid 1 Sodium Chloride 1 Sodium Bicarbonate 1 Rivaroxaban 1 Pentetic Acid 1 PEGPH20 1 Minocycline 1 Ketoconazole 1 Fluorodeoxyglucose F18 1 Fluoridation 1 Estramustine 1 Enzyme-Linked Immunosorbent Assay 1 Doxorubicin 1 Docetaxel 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Thromboembolism × edoxaban × Clear all

NCT04072068 2023-05-30

EDOI

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 4 Completed

Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡